Movatterモバイル変換


[0]ホーム

URL:


US3416530A - Eyeball medication dispensing tablet - Google Patents

Eyeball medication dispensing tablet
Download PDF

Info

Publication number
US3416530A
US3416530AUS531311AUS53131166AUS3416530AUS 3416530 AUS3416530 AUS 3416530AUS 531311 AUS531311 AUS 531311AUS 53131166 AUS53131166 AUS 53131166AUS 3416530 AUS3416530 AUS 3416530A
Authority
US
United States
Prior art keywords
eyeball
medicament
tablet
medication
medication dispensing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US531311A
Inventor
Richard A Ness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to US531311ApriorityCriticalpatent/US3416530A/en
Application grantedgrantedCritical
Publication of US3416530ApublicationCriticalpatent/US3416530A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Description

Dec. 17, 1968 R. A. NESS 3,416,530
EYEBALL MEDICATION DISPENSING TABLET Filed March 2, 1966 2 Sheets-Sheet l INVENTOR.
R/cHARo A. Nsss BY AT TORNE Y5 Dec. 17, 1968 Filed March 2, 1966 FIG. 3
R. A. NESS EYEBALL MEDICATION DISPENS ING TABLET 2 Sheets-Sheet 2 'AT TORNE Y5 United States Patent 3,416,530 EYEBALL MEDICATION DISPENSING TABLET Richard A. Ness, Fergus Falls, Minn. 56537 Filed Mar. 2, 1966, Ser. No. 531,311 7 Claims. (Cl. 128260) This invention relates generally to the treatment of disseases of the eye, and more particularly, to novel means for dispensing medication to the human eyeball.
At the present time, in the treatment of eye diseases, such as glaucoma, medication is applied to the cornea of the eye in liquid or ointment form. In many cases, to be effective, the application of medication to the cornea should be substantially continuous. Such a procedure is highly inconvenient and confining to the patient. At best, the medication is applied at intervals during the day and night. However, the difiiculty with such periodic application is that the eye receives a massive dose at the time of application, and shortly thereafter, substantially all of the medication is washed away by tears, leaving the eye, particularly the cornea thereof, without medication until the next dose is applied.
An important object of this invention is the provision of means whereby medication is applied to the eyeball continuously over an extended period of time.
Another object of this invention is the provision of a medication dispensing device which may be quickly and easily applied to the eyeball, which will dispense medication thereto-at a predetermined rate of speed, and which may be as quickly and easily removed and replaced when the supply of medicament is exhausted.
Still another object of this invention is the provision of a medication dispensing device having means providing a visual indication of the quantity of medicament available to the eyeball.
Yet another object of this invention is the provision of a medication dispensing device which will conform to the curvature of the sclera so as to fit comfortably in the culde-sac of the conjunctiva between the upper eyelid and the eyeball or globe in radially spaced relation to the cornea, and disposed in the path of tear flow to the cornea, whereby to be responsive to flow of tears to dispense medicament thereto.
To the above ends, I provide a medication dispensing tablet-like body of concavo-convex section and of flexible material and having a smooth curved outline, the concave inner surface of said body having a generally spherical radius conforming substantially to the radius of the scleral portion of an eyeball, the body containing a supply of medicament and adapted to dispense the medicament to tears during flow of said tears from the lacrimal gland toward the cornea of the eyeball, when the body is applied to the eyeball as set forth. The above, and still further highly important objects and advantages of this invention will become apparent from the following detailed specification, appended cl-aims and attached drawings.
Referring to the drawings, which illustrate the invention, and in which like reference characters indicate like parts throughout the several views:
FIG. 1 is a view partly in front elevation and partly diagrammatic, of a human eye, illustrating the use of the invention;
FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith, showing the placement of the medication dispensing tablet of this invention;
FIG. 3 is a view in top plan of a preferred form of medication dispensing tablet of this invention;
FIG. 4 is a longitudinal section, taken on the line 44 of FIG. 3;
FIG. 5 is a transverse section taken substantially on the line 5-5 of FIG. 3;
FIG. 6 is a view corresponding ot FIG. 3 but showing a modified form of tablet;
FIG. 7 is a view in perspective of means for packaging the tablet of this invention; and
FIG. 8 is an enlarged transverse section, taken on the line 88 of FIG. 7.
Referring particularly to FIGS. 1 and 2, a human eye is shown, more or less diagrammatically, as comprising an eyeball 1, and upper andlower eyelids 2 and 3 respectively, the eyeball 1 being covered for the greater parts of its area by thesclera 4 and at its anterior portion by thecornea 5. Theeyelids 2 and 3 are lined with a epithelial membrane orconjunctiva 6 which covers the exposed portion of the eyeball including thecornea 5, that portion covering the cornea being transparent, that portion of theconjunctiva 6 which lines the upper eyelid 2 and the underlying portion of thesclera 4 defining a cul-de-sac 7. Upper and lower eyelashes are indicated at 8 and 9 respectively. Other details of the structure of the eyeball 1 are not directly concerned with the structure of the instant invention, detailed showing and description thereof being omitted in the interest of brevity. The usual lacrimal gland associated with the eyeball 1 is shown by dot and dash lines in FIG. 1 and indicated by thenumeral 10.
The preferred embodiment of the invention illustrated in FIGS. l-S, a hollow tablet-like body 11, of concavoconvex cross section, is shown as comprising inner andouter walls 12 and 13 respectively, thewalls 12 and 13 being joined at their marginal edge portions and defining achamber 14 that is filled withmedicament 15. The marginal juncture of thewalls 12 and 13 is rounded, as indicated at 16 in FIGS. 4 and 5, so as to avoid sharp edges and, in the preferred embodiment of the invention, the
outline of thebody 11 is bean-shaped or reniform as shown in FIGS. 1 and 3. Communication between thechamber 14 and the exterior of thebody 11 is had through a plurality ofcapillary openings 17 in thewalls 12 and 13, as well as through the joined edges thereof. The marginal edges of the inner andouter walls 12 and 13 may be joined together by any suitable means, such as heat-sealing, gluing or the like. Preferably, thecapillary openings 17 are disposed in the areas of thewalls 12 and 13 adjacent the marginal edges thereof as shown particularly in FIG. 3.
In order that thebody 11 may comfortably fit in the cul-de-sac 7, the overall dimensions of thebody 11 are quite small. Preferably, the overall length of thebody 11 is approximately fifteen millimeters, the width thereof intermediate its ends being in the neighborhood of eleven or twelve millimeters. Theouter surface 18, which is adapted to be disposed adjacent the sclera, of theinner wall 12 is generally spherical, having a spherical radius of approximately twelve millimeters, corresponding to the radius of the scleral portion of the eyeball. Obviously, the dimensions noted above may be varied in accordance with eyeballs of different sizes. It will be noted, with reference to FIGS. 4 and 5, that thebody 11 is of substantially greater thickness at its central portion than at the marginal edge thereof, whereby to define achamber 14 of a :size to contain sufiicient highly concentrated medication for adequate treatment over at least a days time. Preferably, the maximum thickness of thebody 11 is approximately one to one and one-half millimeters. When thebody 11, filled withmedicament 15, is placed in the cul-de-sac 7, some of the tear liquid flowing from thelacrimal gland 10 to and across the eyeball 1 will enter thechamber 14 through some of thecapillary openings 17, and outwardly therefrom through others of theopenings 17, carrying with it some of themedicament 15. Responsive to blinking action of the upper eyelid 2, the tear liquid and medicament mixture will flow over thecornea 5 which absorbs the medicament, thus administering a constant supply of medicament to the cornea until the supply within thechamber 14 is exhausted. Normally, the lacrimal gland is disposed just slightly above and posteriorly or rearwardly of the cul-de-sac 7 in a depression of the upper, outer wall of the orbit, not shown. The flow of tears from thelacrimal gland 10 is generally diagonally across the cornea toward the puncta, as is wellknown to those skilled in this art, the general direction of tear flow being indicated by arrows in FIG. 1.
The tablet-like body 11 may be made from any suitable material that is flexible, biologically inert, nonellergenic, insoluble in tear liquid, and chemically compatible with the medicament in thechamber 14. Thewalls 12 and 13 of thebody 11 may be made from polyethylene or any other of well-known synthetic plastic materials having the above-mentioned characteristics. The medicament in thechamber 14 comprises the desired medication for treatment and a soluble or semi-soluble carrier or matrix, the matrix being of any suitable substance such as gum acacia, gum tragacanth, or the like. The matrix serves to hold the medication together during fabrication of thebody 11, and operates as a diluent during the medication dispensing operation of thebody 11.
Insertion of thebody 11 into the cul-de-sac 7 and removal of thebody 11 therefrom is a relatively simple and easy operation. Thebody 11 may be mounted on or grasped by a suitable tool or holder, not shown, but which may include a minute suction cup for engaging the outer Wall of thebody 11. The upper eyelid is raised upwardly and outwardly adjacent the outer corner portion of the eye to open the cul-de-sac 7, and thebody 11 inserted and released from the holder. The holder may be one of several types commonly used to insert and remove present day corneal contact lenses, artificial eyes and the like.
The present invention contemplates the use of an indicator dye in themedicament 15 to serve as a visual indication as to the supply of medicament within thechamber 14. For this purpose, a small amount of methylene blue or any suitable dye material is used. So that themedicament 15 may be easily seen, theouter wall 13 of thebody 11 is preferably transparent, theinner wall 12 being preferably opaque and having a color in substantial contrast to the color of themedicament 15 or indicator dye.
The modified form of the invention illustrated in FIG. 6 comprises abody 19 that is generally elliptical in outline but which in all other respects is identical to the form ofbody 11 illustrated in FIGS. 1-5. The parts of thebody 19 shown in FIG. 6, corresponding to similar parts of thebody 11, are indicated by corresponding reference numerals with prime marks added. Thus theouter wall 13 and the marginal edge 16' are provided with capillary openings 17' and it may be assumed that thebody 19 is cross-sectionally similar to thebody 11, as shown in FIGS. 4 and 5.
A preferred means for packaging the tablets of this invention is shown in FIGS. 7 and 8. A relatively thick sheet-like base member 20 is shown as being formed to provide a plurality of upwardly openingpockets 21, each for reception of a different one of the tablets ofbodies 11 or 19, and having upwardly dishedbottom walls 22 which substantially fit the overlying inner wall-s of thebodies 11 or 19. A relativelythin cover sheet 23 overlies thebase member 20 and is releasably adhered to the top surface thereof intermediate thepockets 21 and adjacent the marginal edge of thebase member 20. Preferably, thebase member 20 andcover sheet 23 are made from synthetic plastic sheet material, thecover sheet 23 being preferably transparent so that occupancy of any of thepockets 21 by a tablet may be readily seen. Further, when packaging the tablets, it is desirable to introduce a small amount of the medicament into thevarious pockets 21 to maintain the outer surfaces of the tablets orbodies 11 or 19 in a moist condition for ease of application to the eyeball. Preferably, the upper surfaces of thebase member 20 in thepockets 21 are corrugated, knurled, or otherwise roughened, as indicated at 21a, to prevent the liquid in thepockets 21 from causing thebodies 11 to adhere to thepockets 21, and to break any suction therebetween, which might occur if the surfaces of thepockets 21 were smooth.
It will be appreciated that the outline of thetablets 11 or 19 may be of any curved configuration, such as circular, if desired. Further, thecapillary openings 17 and 17 need not be necessarily circular as shown. If desired, thewalls 12, 13, 12' and 13 may be made from porous material having the characteristics above described in connection with thebody 11. Still further, this invention contemplates a body of the shape or shapes above described, which in itself is a solid body, as distinguished from thebodies 11 or 19 which define inner chambers, but which is in itself sufficiently porous to receive the desired amount of medicament and retain the same until the medicament is gradually leached therefrom under the action of tear flow. In such a modification, the body, not shown, may be made from suitable material of a given color, the medication being dyed to a contrasting color, whereby to provide an indication as to the presence or absence of medication in the porous body.
While I have shown and described a preferred form and a single modification of medication dispensing tablet, it will be understood that the same may be produced in other different shapes, such as circular, and that other modifications may be made without departure from the spirit and scope of the invention, as defined in the claims.
What is claimed is:
1. A medication dispensing tablet for a human eyeball, said tablet comprising a cross-sectionally concavoconvex body of flexible material for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and upper eyelid in generally radially spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lacrimal gland, said body having a curved outline and an inner concave surface, said concave surface having a generally spherical radius substantially equal to that of the outer scleral surface of an eyeball, and a supply of medicament contained within said body, said body being responsive to flow of tears thereover, when the body is applied to the eyeball, to dispense said medicament to the eyeball generally above the cornea, said body being so constructed and arranged that the rate of dispensing said medicament is dependent upon the rate of flow of tears over said body.
2. The medication dispensing tablet defined in claim 1 in which the marginal outline of said body is generally elliptical.
3. The medication dispensing tablet defined in claim 1 in which the marginal outline of said boy is generally bean-shaped.
4. The medication dispensing tablet defined in claim 1 in which said body comprises a pair of inner and outer walls defining a chamber for the medicament, said body having multiple perforations through at least one of said walls, whereby the medicament in said chamber seeps outwardly fro-m said chamber into the tear flow over saidbody 5. The medication dispensing tablet defined in claim 1 characterized by dye in said medicament for visual indication of the presence of medicament in said body.
5 6 6. The medication dispensing tablet defined in claim References Cited f! which tthe 03ml Of Of saiddbodayl UNITED STATES PATENTS 1s ransparen, 5211 me icarnen incu ing a me 1cm agent and a soluble matrix, characterized by a dye of a 772,028 10/1904 Carpenter 128-260 given color in said medicament, for visual indication of 5 32? 52223;
the presence of medicament in said chamber.
7. The medication dispensing tablet defined in claim 6l 4 in which the inner one of the Walls of said body is dyed ADELE EAGER Puma), Exammer' to a given color, the dye in said medicament being of a U S C1 X R color substantially different from that of the colored inner 10 Wall. 128261, 268; 16759; 20663.2

Claims (1)

1. A MEDICIATION DISPENSING TABLET FOR A HUMAN EYE BALL, SAID TABLET COMPRISING A CROSS-SECTIONALLY CONCAVOCONVEX BODY OF FLEXIBLE MATERIAL FOR INSERTION INTO THE CUL-DE-SAC OF THE CONJUNCTIVA BETWEEN THE SCLERA OF THE EYEBALL AND UPPER EYELID IN GENERALLY RADIALLY SPACED RELATION TO THE CORNEA OF THE EYEBALL AND IN THE PATH OF FLOW OF TEARS FROM THE ASSOCIATED LACRIMAL GLAND, SAID BODY HAVING A CURVED OUTLINE AND AN INNER CONCAVE SURFACE, SAID CONCAVE SURFACE HAVING A GENERALLY SPHERICAL RADIUS SUBSTANTIALLY EQUAL TO THAT OF THE OUTER SCLERAL SURFACE OF AN EYEBALL, AND A SUPPLY OF MEDICAMENT CONTAINED WITHIN SAID BODY, SAID BODY BEING RESPONSIVE TO FLOW OF
US531311A1966-03-021966-03-02Eyeball medication dispensing tabletExpired - LifetimeUS3416530A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US531311AUS3416530A (en)1966-03-021966-03-02Eyeball medication dispensing tablet

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US531311AUS3416530A (en)1966-03-021966-03-02Eyeball medication dispensing tablet

Publications (1)

Publication NumberPublication Date
US3416530Atrue US3416530A (en)1968-12-17

Family

ID=24117121

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US531311AExpired - LifetimeUS3416530A (en)1966-03-021966-03-02Eyeball medication dispensing tablet

Country Status (1)

CountryLink
US (1)US3416530A (en)

Cited By (146)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3618604A (en)*1969-06-091971-11-09Alza CorpOcular insert
US3625214A (en)*1970-05-181971-12-07Alza CorpDrug-delivery device
US3626940A (en)*1969-05-021971-12-14Alza CorpOcular insert
US3630200A (en)*1969-06-091971-12-28Alza CorpOcular insert
DE2243986A1 (en)*1971-09-091973-03-29Alza Corp BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT
US3814097A (en)*1972-02-141974-06-04Ici LtdDressing
US3826258A (en)*1972-02-071974-07-30S AbrahamGradual release medicine carrier
US3828777A (en)*1971-11-081974-08-13Alza CorpMicroporous ocular device
US3845770A (en)*1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3853116A (en)*1971-06-211974-12-10Investors In Ventures IncImplant methods and devices for influencing body fluids
US3926188A (en)*1974-11-141975-12-16Alza CorpLaminated drug dispenser
USB520277I5 (en)*1971-09-091976-02-17
DE2547378A1 (en)*1974-10-241976-04-29Searle & Co DEVICE WITH LOCKED MICROCHAMBERS FOR DISPENSING A MEDICINAL PRODUCT
US4136173A (en)*1977-01-311979-01-23American Home Products Corp.Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177A (en)*1977-01-311979-01-23American Home Products Corp.Xanthan gum therapeutic compositions
US4136178A (en)*1977-01-311979-01-23American Home Products Corp.Locust bean gum therapeutic compositions
US4201210A (en)*1976-06-221980-05-06The United States Of America As Represented By The Secretary Of AgricultureVeterinary ocular ring device for sustained drug release
US4304226A (en)*1980-03-031981-12-08The Procter & Gamble CompanyVaginal contraceptive
US4959217A (en)*1986-05-221990-09-25Syntex (U.S.A.) Inc.Delayed/sustained release of macromolecules
WO1993007840A1 (en)*1991-10-151993-04-29Advanced Corneal Systems, Inc.Enzyme-orthokeratology
WO1993019707A1 (en)*1992-04-021993-10-14Bausch & Lomb IncorporatedOphthalmic article
US5378475A (en)*1991-02-211995-01-03University Of Kentucky Research FoundationSustained release drug delivery devices
US5472436A (en)*1994-07-261995-12-05Fremstad; Daria A.Ocular appliance for delivering medication
US5773019A (en)*1995-09-271998-06-30The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the body
US5788957A (en)*1991-10-151998-08-04Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5876438A (en)*1993-08-021999-03-02Houston Biotechnology IncorporatedPolymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5902598A (en)*1997-08-281999-05-11Control Delivery Systems, Inc.Sustained release drug delivery devices
US6063116A (en)*1994-10-262000-05-16Medarex, Inc.Modulation of cell proliferation and wound healing
US6161544A (en)*1998-01-282000-12-19Keratoform, Inc.Methods for accelerated orthokeratology
WO2001032140A1 (en)1999-11-042001-05-10Btg Int LtdOcular insert
US6303102B1 (en)2000-09-072001-10-16Kenneth SchlichteCutaneously applied biodegradable tell-tale having controllable clearing time
US6331313B1 (en)1999-10-222001-12-18Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375972B1 (en)2000-04-262002-04-23Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6413245B1 (en)1999-10-212002-07-02Alcon Universal Ltd.Sub-tenon drug delivery
US6413540B1 (en)1999-10-212002-07-02Alcon Universal Ltd.Drug delivery device
US6416777B1 (en)1999-10-212002-07-09Alcon Universal Ltd.Ophthalmic drug delivery device
US20020106395A1 (en)*2001-01-032002-08-08Brubaker Michael J.Sustained release drug delivery devices with prefabricated permeable plugs
US20020110635A1 (en)*2001-01-262002-08-15Brubaker Michael J.Process for the production of sustained release drug delivery devices
US20020188282A1 (en)*2001-02-132002-12-12Robert GreenbergImplantable drug delivery device
US20030176854A1 (en)*2002-03-112003-09-18Alcon, Inc.Implantable drug delivery system
US6699493B2 (en)2000-11-292004-03-02Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20040092911A1 (en)*2001-07-232004-05-13Yoseph YaacobiOphthalmic drug delivery device
US6756049B2 (en)2000-12-292004-06-29Bausch & Lomb IncorporatedSustained release drug delivery devices
US6756058B2 (en)2001-01-032004-06-29Bausch & Lomb IncorporatedSustained release drug delivery devices with multiple agents
US20040133155A1 (en)*2000-08-302004-07-08Varner Sign EricksonDevices for intraocular drug delivery
US20050013845A1 (en)*2002-11-122005-01-20Warren Stephen L.Adhesive bioerodible ocular drug delivery system
US20050019371A1 (en)*2003-05-022005-01-27Anderson Aron B.Controlled release bioactive agent delivery device
US20060039952A1 (en)*2003-07-102006-02-23Yoseph YaacobiOphthalmic drug delivery device
US20060067966A1 (en)*1995-06-022006-03-30Allergan, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060134176A1 (en)*2004-12-222006-06-22Bausch & Lomb IncorporatedPharmaceutical delivery system and method of use
US7094226B2 (en)2001-07-232006-08-22Alcon, Inc.Ophthalmic drug delivery device
US20060210604A1 (en)*2004-10-042006-09-21Eric DadeyOcular delivery of polymeric delivery formulations
US20060270968A1 (en)*2003-03-212006-11-30Robert GreenbergTransretinal implant and method of manufacture
US20070092570A1 (en)*1999-10-212007-04-26Missel Paul JDrug delivery device
US20070112318A1 (en)*2003-08-262007-05-17Leahy Charles DOcular drug delivery device
US20070244442A1 (en)*2004-12-222007-10-18Chowhan Masood ADevice for Ophthalmic Drug Delivery
US20070280992A1 (en)*2004-10-042007-12-06Qlt Usa, Inc.Sustained delivery formulations of rapamycin compounds
US20070298074A1 (en)*2006-06-232007-12-27Allergan, Inc.Steroid-containing sustained release intraocular implants and related methods
US20090093789A1 (en)*2007-10-092009-04-09Alcon Research, Ltd.Method of Delivering A Rate And Temperature - Dependent Substance Into The Eye
US20090093788A1 (en)*2007-10-092009-04-09Alcon Research, Ltd.Thermal Coefficient Driven Drug Pellet Size For Ophthalmic Injection
US7563255B2 (en)2001-05-032009-07-21Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereof
US7585517B2 (en)2003-09-182009-09-08Macusight, Inc.Transscleral delivery
US20100004609A1 (en)*2008-07-032010-01-07Michael CampionEye coloring systems
US7708711B2 (en)2000-04-142010-05-04Glaukos CorporationOcular implant with therapeutic agents and methods thereof
US20100226962A1 (en)*2009-03-032010-09-09Rodstrom Theron RPeri-corneal drug delivery device
WO2010147653A1 (en)2009-06-162010-12-23Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US20110028807A1 (en)*1996-09-042011-02-03Marcio Marc AbreuContact lens for collecting tears and detecting at least one analyte
WO2011039648A1 (en)2009-09-302011-04-07Glaxo Wellcome Manufacturing Pte Ltd.Methods of administration and treatment
EP2329821A1 (en)2005-11-292011-06-08GlaxoSmithKline LLCTreatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US20110184358A1 (en)*2010-01-272011-07-28Weiner Alan LPulsatile peri-corneal drug delivery device
US8034370B2 (en)2003-01-092011-10-11Allergan, Inc.Ocular implant made by a double extrusion process
EP2374451A2 (en)2005-07-272011-10-12University of Florida Research Foundation, Inc.Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
US20120078362A1 (en)*2009-05-182012-03-29Dose Medical CorporationDrug eluting ocular implant
US8177747B2 (en)2009-12-222012-05-15Alcon Research, Ltd.Method and apparatus for drug delivery
US8222271B2 (en)2006-03-232012-07-17Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8242099B2 (en)2000-07-052012-08-14Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US8246974B2 (en)2003-05-022012-08-21Surmodics, Inc.Medical devices and methods for producing the same
US8277830B2 (en)2009-01-292012-10-02Forsight Vision4, Inc.Posterior segment drug delivery
WO2012174064A1 (en)2011-06-142012-12-20Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US8367097B2 (en)2005-02-092013-02-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8372036B2 (en)2009-05-062013-02-12Alcon Research, Ltd.Multi-layer heat assembly for a drug delivery device
WO2013058809A1 (en)2011-10-192013-04-25Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en)2011-12-012013-06-06Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US8486052B2 (en)2001-06-122013-07-16The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US8492400B2 (en)2006-02-092013-07-23Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8623395B2 (en)2010-01-292014-01-07Forsight Vision4, Inc.Implantable therapeutic device
US8663639B2 (en)2005-02-092014-03-04Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US8715712B2 (en)2011-09-142014-05-06Forsight Vision5, Inc.Ocular insert apparatus and methods
US8765166B2 (en)2010-05-172014-07-01Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US8802129B2 (en)2004-04-302014-08-12Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8905963B2 (en)2010-08-052014-12-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
JP5671183B1 (en)*2014-08-282015-02-18株式会社ユニバーサルビュー Eyelid interior tools
WO2015071427A1 (en)2013-11-142015-05-21Eyed PharmaEye device
US9102105B2 (en)2011-09-132015-08-11Vista Scientific LlcMethod for forming an ocular drug delivery device
EP2944628A1 (en)2011-11-302015-11-18Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US9308355B2 (en)2012-06-012016-04-12Surmodies, Inc.Apparatus and methods for coating medical devices
US9421126B2 (en)2009-06-032016-08-23Forsight Vision5, Inc.Anterior segment drug delivery
US9474756B2 (en)2014-08-082016-10-25Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en)2010-08-052016-11-15Forsight Vision4, Inc.Implantable therapeutic device
US9526654B2 (en)2013-03-282016-12-27Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US9668915B2 (en)2010-11-242017-06-06Dose Medical CorporationDrug eluting ocular implant
US9750636B2 (en)2012-10-262017-09-05Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US9827401B2 (en)2012-06-012017-11-28Surmodics, Inc.Apparatus and methods for coating medical devices
US9883968B2 (en)2011-09-162018-02-06Forsight Vision4, Inc.Fluid exchange apparatus and methods
US20180092771A1 (en)*2013-11-042018-04-05Vance M. ThompsonConjunctival cover and methods therefor
US9968603B2 (en)2013-03-142018-05-15Forsight Vision4, Inc.Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10010502B2 (en)2015-05-192018-07-03Amorphex Therapeutics LlcDevice that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US10010448B2 (en)2012-02-032018-07-03Forsight Vision4, Inc.Insertion and removal methods and apparatus for therapeutic devices
US10166142B2 (en)2010-01-292019-01-01Forsight Vision4, Inc.Small molecule delivery with implantable therapeutic device
US10206813B2 (en)2009-05-182019-02-19Dose Medical CorporationImplants with controlled drug delivery features and methods of using same
US10245178B1 (en)2011-06-072019-04-02Glaukos CorporationAnterior chamber drug-eluting ocular implant
US10258503B2 (en)2014-07-152019-04-16Forsight Vision4, Inc.Ocular implant delivery device and method
WO2019136358A1 (en)*2018-01-052019-07-11Iveena Delivery Systems, Inc.Treatment of myopic progression
US10398592B2 (en)2011-06-282019-09-03Forsight Vision4, Inc.Diagnostic methods and apparatus
US10406029B2 (en)2001-04-072019-09-10Glaukos CorporationOcular system with anchoring implant and therapeutic agent
JP2019176912A (en)*2018-03-302019-10-17真一 芦田Ophthalmic device, ophthalmic medicament administration device, and ophthalmic mounted article
US10485701B2 (en)2002-04-082019-11-26Glaukos CorporationDevices and methods for glaucoma treatment
US10500091B2 (en)2014-11-102019-12-10Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US10596330B2 (en)2015-08-262020-03-24Medtronic Xomed, Inc.Resorbable, drug-eluting submucosal turbinate implant device and method
US10617557B2 (en)2010-08-052020-04-14Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US10828473B2 (en)2001-04-072020-11-10Glaukos CorporationOcular implant delivery system and methods thereof
US10828195B2 (en)2006-11-102020-11-10Glaukos CorporationUveoscleral shunt and methods for implanting same
USD901683S1 (en)2017-10-272020-11-10Glaukos CorporationImplant delivery apparatus
US10874548B2 (en)2010-11-192020-12-29Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US10959941B2 (en)2014-05-292021-03-30Glaukos CorporationImplants with controlled drug delivery features and methods of using same
WO2021081117A2 (en)2019-10-242021-04-29Labombard Denis EOcular device and drug delivery system, with case
US11116625B2 (en)2017-09-282021-09-14Glaukos CorporationApparatus and method for controlling placement of intraocular implants
US11197780B2 (en)2012-03-262021-12-14Glaukos CorporationSystem and method for delivering multiple ocular implants
US11224602B2 (en)2015-04-132022-01-18Forsight Vision5, Inc.Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11281023B2 (en)2016-10-172022-03-22Tearoptix, Inc.Tear shaping for refractive correction
US11318043B2 (en)2016-04-202022-05-03Dose Medical CorporationBioresorbable ocular drug delivery device
US11376040B2 (en)2017-10-062022-07-05Glaukos CorporationSystems and methods for delivering multiple ocular implants
US11419759B2 (en)2017-11-212022-08-23Forsight Vision4, Inc.Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en)2015-11-202022-09-06Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US11559430B2 (en)2013-03-152023-01-24Glaukos CorporationGlaucoma stent and methods thereof for glaucoma treatment
US11567348B2 (en)2015-03-112023-01-31Tearoptix, Inc.Tear shaping for refractive correction
US11564833B2 (en)2015-09-252023-01-31Glaukos CorporationPunctal implants with controlled drug delivery features and methods of using same
US11617680B2 (en)2016-04-052023-04-04Forsight Vision4, Inc.Implantable ocular drug delivery devices
US11628466B2 (en)2018-11-292023-04-18Surmodics, Inc.Apparatus and methods for coating medical devices
WO2023073706A1 (en)2021-10-272023-05-04Avisi Ltd.Ophthalmic device
US11703695B2 (en)2018-04-062023-07-18Tearoptix, Inc.Tear shaping for refractive correction
US11819590B2 (en)2019-05-132023-11-21Surmodics, Inc.Apparatus and methods for coating medical devices
US11925578B2 (en)2015-09-022024-03-12Glaukos CorporationDrug delivery implants with bi-directional delivery capacity
USD1033637S1 (en)2022-01-242024-07-02Forsight Vision4, Inc.Fluid exchange device
WO2024224394A1 (en)2023-04-272024-10-31Avisi Ltd.Elastomeric matrices comprising polyvinyl alcohol
US12226525B2 (en)2006-03-312025-02-18Mati Therapeutics, Inc.Nasolacrimal drainage system implants for drug therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US772028A (en)*1903-11-131904-10-11George A CarpenterDevice for putting medicine into eyes.
US2347488A (en)*1943-04-051944-04-25John H LawiorOptical lens
US3302646A (en)*1964-01-101967-02-07Charles A BehneyApparatus for treating eye infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US772028A (en)*1903-11-131904-10-11George A CarpenterDevice for putting medicine into eyes.
US2347488A (en)*1943-04-051944-04-25John H LawiorOptical lens
US3302646A (en)*1964-01-101967-02-07Charles A BehneyApparatus for treating eye infection

Cited By (295)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3626940A (en)*1969-05-021971-12-14Alza CorpOcular insert
US3618604A (en)*1969-06-091971-11-09Alza CorpOcular insert
US3630200A (en)*1969-06-091971-12-28Alza CorpOcular insert
US3625214A (en)*1970-05-181971-12-07Alza CorpDrug-delivery device
US3853116A (en)*1971-06-211974-12-10Investors In Ventures IncImplant methods and devices for influencing body fluids
USB520277I5 (en)*1971-09-091976-02-17
US3995635A (en)*1971-09-091976-12-07Alza CorporationOcular insert
DE2243986A1 (en)*1971-09-091973-03-29Alza Corp BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT
US3828777A (en)*1971-11-081974-08-13Alza CorpMicroporous ocular device
US3826258A (en)*1972-02-071974-07-30S AbrahamGradual release medicine carrier
US3814097A (en)*1972-02-141974-06-04Ici LtdDressing
US3845770A (en)*1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
DE2547378A1 (en)*1974-10-241976-04-29Searle & Co DEVICE WITH LOCKED MICROCHAMBERS FOR DISPENSING A MEDICINAL PRODUCT
US3926188A (en)*1974-11-141975-12-16Alza CorpLaminated drug dispenser
US4201210A (en)*1976-06-221980-05-06The United States Of America As Represented By The Secretary Of AgricultureVeterinary ocular ring device for sustained drug release
US4136173A (en)*1977-01-311979-01-23American Home Products Corp.Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en)*1977-01-311979-01-23American Home Products Corp.Locust bean gum therapeutic compositions
US4136177A (en)*1977-01-311979-01-23American Home Products Corp.Xanthan gum therapeutic compositions
US4304226A (en)*1980-03-031981-12-08The Procter & Gamble CompanyVaginal contraceptive
US4959217A (en)*1986-05-221990-09-25Syntex (U.S.A.) Inc.Delayed/sustained release of macromolecules
US5378475A (en)*1991-02-211995-01-03University Of Kentucky Research FoundationSustained release drug delivery devices
US5270051A (en)*1991-10-151993-12-14Harris Donald HEnzyme-orthokeratology
WO1993007840A1 (en)*1991-10-151993-04-29Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5626865A (en)*1991-10-151997-05-06Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US6132735A (en)*1991-10-152000-10-17Ista Pharmaceutical, Inc.Enzyme-orthokeratology
US5788957A (en)*1991-10-151998-08-04Advanced Corneal Systems, Inc.Enzyme-orthokeratology
WO1993019707A1 (en)*1992-04-021993-10-14Bausch & Lomb IncorporatedOphthalmic article
US5876438A (en)*1993-08-021999-03-02Houston Biotechnology IncorporatedPolymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5472436A (en)*1994-07-261995-12-05Fremstad; Daria A.Ocular appliance for delivering medication
US6063116A (en)*1994-10-262000-05-16Medarex, Inc.Modulation of cell proliferation and wound healing
US20060067966A1 (en)*1995-06-022006-03-30Allergan, Inc.Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en)*1995-09-271998-06-30The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the body
US20110028807A1 (en)*1996-09-042011-02-03Marcio Marc AbreuContact lens for collecting tears and detecting at least one analyte
US5902598A (en)*1997-08-281999-05-11Control Delivery Systems, Inc.Sustained release drug delivery devices
US6161544A (en)*1998-01-282000-12-19Keratoform, Inc.Methods for accelerated orthokeratology
US7943162B2 (en)1999-10-212011-05-17Alcon, Inc.Drug delivery device
US6669950B2 (en)1999-10-212003-12-30Alcon, Inc.Ophthalmic drug delivery device
US20040131654A1 (en)*1999-10-212004-07-08Yoseph YaacobiOphthalmic drug delivery device
US20040131655A1 (en)*1999-10-212004-07-08Yoseph YaacobiOphthalmic drug delivery device
US6413245B1 (en)1999-10-212002-07-02Alcon Universal Ltd.Sub-tenon drug delivery
US6413540B1 (en)1999-10-212002-07-02Alcon Universal Ltd.Drug delivery device
US6416777B1 (en)1999-10-212002-07-09Alcon Universal Ltd.Ophthalmic drug delivery device
US20070092570A1 (en)*1999-10-212007-04-26Missel Paul JDrug delivery device
US6808719B2 (en)1999-10-212004-10-26Alcon, Inc.Drug delivery device
US20050112175A1 (en)*1999-10-212005-05-26Yoseph YaacobiDrug delivery device
US6331313B1 (en)1999-10-222001-12-18Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001030323A3 (en)*1999-10-222002-02-21Oculex Pharm IncControlled-release biocompatible ocular drug delivery implant devices and methods
WO2001032140A1 (en)1999-11-042001-05-10Btg Int LtdOcular insert
US6264971B1 (en)*1999-11-042001-07-24Btg International LimitedOcular insert
US8348877B2 (en)2000-04-142013-01-08Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US9066782B2 (en)2000-04-142015-06-30Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US9789001B2 (en)2000-04-142017-10-17Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US7708711B2 (en)2000-04-142010-05-04Glaukos CorporationOcular implant with therapeutic agents and methods thereof
EP1982701A2 (en)2000-04-262008-10-22pSivida IncSustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof
US6375972B1 (en)2000-04-262002-04-23Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8242099B2 (en)2000-07-052012-08-14Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US10206934B2 (en)2000-07-052019-02-19Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US9775849B2 (en)2000-07-052017-10-03Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US9012437B2 (en)2000-07-052015-04-21Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US20040133155A1 (en)*2000-08-302004-07-08Varner Sign EricksonDevices for intraocular drug delivery
US8096972B2 (en)2000-08-302012-01-17Johns Hopkins UniversityDevices for intraocular drug delivery
US6303102B1 (en)2000-09-072001-10-16Kenneth SchlichteCutaneously applied biodegradable tell-tale having controllable clearing time
US8071120B2 (en)2000-11-292011-12-06Allergan, Inc.Methods for treating neovascularization and intravitreal implants
US6699493B2 (en)2000-11-292004-03-02Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US9283178B2 (en)2000-11-292016-03-15Allergan, Inc.Methods for treating edema in the eye and intraocular implants for use therefor
US7767223B2 (en)2000-11-292010-08-03Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US7846468B2 (en)2000-11-292010-12-07Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US7033605B2 (en)2000-11-292006-04-25Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8088407B2 (en)2000-11-292012-01-03Allergan, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US8828446B2 (en)2000-11-292014-09-09Allergan, Inc.Method for reducing transplant rejection in the eye and intraocular implants for use therefor
US20060198871A1 (en)*2000-11-292006-09-07Allergan, Inc.Methods for treating neovascularization and intravitreal implants
US20050249710A1 (en)*2000-11-292005-11-10Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use
US8043628B2 (en)2000-11-292011-10-25Allergan, Inc.Methods for reducing edema
US7625582B2 (en)2000-11-292009-12-01Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20040137034A1 (en)*2000-11-292004-07-15Wong Vernon G.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US9592242B2 (en)2000-11-292017-03-14Allergan, Inc.Methods for treating edema in the eye and intraocular implants for use therefor
US6756049B2 (en)2000-12-292004-06-29Bausch & Lomb IncorporatedSustained release drug delivery devices
US20040208909A1 (en)*2000-12-292004-10-21Brubaker Michael JSustained release drug delivery devices
US6964781B2 (en)2001-01-032005-11-15Bausch & Lomb IncorporatedSustained release drug delivery devices with prefabricated permeable plugs
US6756058B2 (en)2001-01-032004-06-29Bausch & Lomb IncorporatedSustained release drug delivery devices with multiple agents
US20020106395A1 (en)*2001-01-032002-08-08Brubaker Michael J.Sustained release drug delivery devices with prefabricated permeable plugs
US6991808B2 (en)2001-01-262006-01-31Bausch & Lomb Inc.Process for the production of sustained release drug delivery devices
US20020110635A1 (en)*2001-01-262002-08-15Brubaker Michael J.Process for the production of sustained release drug delivery devices
US20060062826A1 (en)*2001-01-262006-03-23Brubaker Michael JProcess for the production of sustained release drug delivery devices
US7181287B2 (en)2001-02-132007-02-20Second Sight Medical Products, Inc.Implantable drug delivery device
US7527621B2 (en)2001-02-132009-05-05Second Sight Medical Products, Inc.Implantable drug delivery device
US20070026048A1 (en)*2001-02-132007-02-01Robert GreenbergImplantable drug delivery device
US20020188282A1 (en)*2001-02-132002-12-12Robert GreenbergImplantable drug delivery device
US10828473B2 (en)2001-04-072020-11-10Glaukos CorporationOcular implant delivery system and methods thereof
US10406029B2 (en)2001-04-072019-09-10Glaukos CorporationOcular system with anchoring implant and therapeutic agent
US7563255B2 (en)2001-05-032009-07-21Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereof
US8486052B2 (en)2001-06-122013-07-16The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US9180046B2 (en)2001-06-122015-11-10The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US10470924B2 (en)2001-06-122019-11-12The Johns Hopkins UniversityReservoir device for intraocular drug delivery
US9522082B2 (en)2001-06-122016-12-20The Johns Hopkins UniversityReservoir device for intraocular drug delivery
US20040092911A1 (en)*2001-07-232004-05-13Yoseph YaacobiOphthalmic drug delivery device
US6986900B2 (en)2001-07-232006-01-17Alcon, Inc.Ophthalmic drug delivery device
US7094226B2 (en)2001-07-232006-08-22Alcon, Inc.Ophthalmic drug delivery device
US7621907B2 (en)2002-03-112009-11-24Alcon, Inc.Implantable drug delivery system
US20030176854A1 (en)*2002-03-112003-09-18Alcon, Inc.Implantable drug delivery system
US20100022945A1 (en)*2002-03-112010-01-28Theron Robert RodstromImplantable drug delivery system
US10485701B2 (en)2002-04-082019-11-26Glaukos CorporationDevices and methods for glaucoma treatment
US20080268021A1 (en)*2002-11-122008-10-30Qlt Usa, Inc.Adhesive bioerodible ocular drug delivery system
US20050013845A1 (en)*2002-11-122005-01-20Warren Stephen L.Adhesive bioerodible ocular drug delivery system
US8318070B2 (en)2003-01-092012-11-27Allergan, Inc.Ocular implant made by a double extrusion process
US8034370B2 (en)2003-01-092011-10-11Allergan, Inc.Ocular implant made by a double extrusion process
US9192511B2 (en)2003-01-092015-11-24Allergan, Inc.Ocular implant made by a double extrusion process
US8034366B2 (en)2003-01-092011-10-11Allergan, Inc.Ocular implant made by a double extrusion process
US10076526B2 (en)2003-01-092018-09-18Allergan, Inc.Ocular implant made by a double extrusion process
US8506987B2 (en)2003-01-092013-08-13Allergan, Inc.Ocular implant made by a double extrusion process
US8778381B2 (en)2003-01-092014-07-15Allergan, Inc.Ocular implant made by a double extrusion process
US10702539B2 (en)2003-01-092020-07-07Allergan, Inc.Ocular implant made by a double extrusion process
US20060270968A1 (en)*2003-03-212006-11-30Robert GreenbergTransretinal implant and method of manufacture
US9993367B2 (en)2003-03-212018-06-12Second Sight Medical Products, Inc.Transretinal implant and method of manufacture
US8021680B2 (en)2003-05-022011-09-20Surmodics, Inc.Controlled release bioactive agent delivery device
US20050019371A1 (en)*2003-05-022005-01-27Anderson Aron B.Controlled release bioactive agent delivery device
US7824704B2 (en)2003-05-022010-11-02Surmodics, Inc.Controlled release bioactive agent delivery device
US7976862B2 (en)2003-05-022011-07-12Surmodics, Inc.Controlled release bioactive agent delivery device
US8246974B2 (en)2003-05-022012-08-21Surmodics, Inc.Medical devices and methods for producing the same
US8034369B2 (en)2003-05-022011-10-11Surmodics, Inc.Controlled release bioactive agent delivery device
US20060039952A1 (en)*2003-07-102006-02-23Yoseph YaacobiOphthalmic drug delivery device
US8679078B2 (en)2003-08-262014-03-25Vista Scientific LlcOcular drug delivery device
US20070112318A1 (en)*2003-08-262007-05-17Leahy Charles DOcular drug delivery device
US8287504B2 (en)2003-08-262012-10-16Vista Scientific LlcOcular drug delivery device
US20100331796A1 (en)*2003-08-262010-12-30Vista Scientific LlcOcular drug delivery device
US8167855B2 (en)2003-08-262012-05-01Vista Scientific LlcOcular drug delivery device
US7585517B2 (en)2003-09-182009-09-08Macusight, Inc.Transscleral delivery
US8911768B2 (en)2004-04-302014-12-16Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US9233071B2 (en)2004-04-302016-01-12Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US8802129B2 (en)2004-04-302014-08-12Allergan, Inc.Methods for treating retinopathy with extended therapeutic effect
US20060210604A1 (en)*2004-10-042006-09-21Eric DadeyOcular delivery of polymeric delivery formulations
US20070280992A1 (en)*2004-10-042007-12-06Qlt Usa, Inc.Sustained delivery formulations of rapamycin compounds
US8313763B2 (en)2004-10-042012-11-20Tolmar Therapeutics, Inc.Sustained delivery formulations of rapamycin compounds
US20060134176A1 (en)*2004-12-222006-06-22Bausch & Lomb IncorporatedPharmaceutical delivery system and method of use
US20070244442A1 (en)*2004-12-222007-10-18Chowhan Masood ADevice for Ophthalmic Drug Delivery
US8637070B2 (en)2005-02-092014-01-28Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US9387165B2 (en)2005-02-092016-07-12Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US8367097B2 (en)2005-02-092013-02-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8927005B2 (en)2005-02-092015-01-06Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US9381153B2 (en)2005-02-092016-07-05Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US8663639B2 (en)2005-02-092014-03-04Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
EP2374451A2 (en)2005-07-272011-10-12University of Florida Research Foundation, Inc.Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
EP2329821A1 (en)2005-11-292011-06-08GlaxoSmithKline LLCTreatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
US8658667B2 (en)2006-02-092014-02-25Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US8492400B2 (en)2006-02-092013-07-23Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US9452156B2 (en)2006-03-232016-09-27Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8486960B2 (en)2006-03-232013-07-16Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US8222271B2 (en)2006-03-232012-07-17Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US12226525B2 (en)2006-03-312025-02-18Mati Therapeutics, Inc.Nasolacrimal drainage system implants for drug therapy
US8802128B2 (en)2006-06-232014-08-12Allergan, Inc.Steroid-containing sustained release intraocular implants and related methods
US20070298074A1 (en)*2006-06-232007-12-27Allergan, Inc.Steroid-containing sustained release intraocular implants and related methods
US12186237B2 (en)2006-11-102025-01-07Glaukos CorporationUveoscleral shunt and methods for implanting same
US10828195B2 (en)2006-11-102020-11-10Glaukos CorporationUveoscleral shunt and methods for implanting same
US20090093789A1 (en)*2007-10-092009-04-09Alcon Research, Ltd.Method of Delivering A Rate And Temperature - Dependent Substance Into The Eye
US20090093788A1 (en)*2007-10-092009-04-09Alcon Research, Ltd.Thermal Coefficient Driven Drug Pellet Size For Ophthalmic Injection
US20100004609A1 (en)*2008-07-032010-01-07Michael CampionEye coloring systems
US8382725B2 (en)*2008-07-032013-02-26Michael CampionEye coloring systems
US9066779B2 (en)2009-01-292015-06-30Forsight Vision4, Inc.Implantable therapeutic device
US11642310B2 (en)2009-01-292023-05-09Forsight Vision4, Inc.Posterior segment drug delivery
US8795712B2 (en)2009-01-292014-08-05Forsight Vision4, Inc.Posterior segment drug delivery
US9417238B2 (en)2009-01-292016-08-16Forsight Vision4, Inc.Posterior segment drug delivery
US9851351B2 (en)2009-01-292017-12-26Forsight Vision4, Inc.Posterior segment drug delivery
US8277830B2 (en)2009-01-292012-10-02Forsight Vision4, Inc.Posterior segment drug delivery
US10656152B2 (en)2009-01-292020-05-19Forsight Vision4, Inc.Posterior segment drug delivery
US10813788B2 (en)2009-01-292020-10-27Forsight Vision4, Inc.Implantable therapeutic device
US8298578B2 (en)2009-01-292012-10-30Forsight Vision4, Inc.Posterior segment drug delivery
US8399006B2 (en)2009-01-292013-03-19Forsight Vision4, Inc.Posterior segment drug delivery
US8808727B2 (en)2009-01-292014-08-19Forsight Vision4, Inc.Posterior segment drug delivery
US20100226962A1 (en)*2009-03-032010-09-09Rodstrom Theron RPeri-corneal drug delivery device
US8372036B2 (en)2009-05-062013-02-12Alcon Research, Ltd.Multi-layer heat assembly for a drug delivery device
US8632511B2 (en)2009-05-062014-01-21Alcon Research, Ltd.Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US12201557B2 (en)2009-05-182025-01-21Dose Medical CorporationDrug eluting ocular implant and method of treating an ocular disorder
US11426306B2 (en)2009-05-182022-08-30Dose Medical CorporationImplants with controlled drug delivery features and methods of using same
US12376989B2 (en)2009-05-182025-08-05Glaukos CorporationDrug eluting ocular implants and methods of treating an ocular disorder
US20120078362A1 (en)*2009-05-182012-03-29Dose Medical CorporationDrug eluting ocular implant
US10813789B2 (en)2009-05-182020-10-27Dose Medical CorporationDrug eluting ocular implant
US12201555B2 (en)2009-05-182025-01-21Dose Medical CorporationDrug eluting ocular implant
US10206813B2 (en)2009-05-182019-02-19Dose Medical CorporationImplants with controlled drug delivery features and methods of using same
US10004636B2 (en)2009-06-032018-06-26Forsight Vision5, Inc.Anterior segment drug delivery
US9421126B2 (en)2009-06-032016-08-23Forsight Vision5, Inc.Anterior segment drug delivery
US10736774B2 (en)2009-06-032020-08-11Forsight Vision5, Inc.Anterior segment drug delivery
EP3100723A1 (en)2009-06-162016-12-07Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2010147653A1 (en)2009-06-162010-12-23Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2011039648A1 (en)2009-09-302011-04-07Glaxo Wellcome Manufacturing Pte Ltd.Methods of administration and treatment
US8177747B2 (en)2009-12-222012-05-15Alcon Research, Ltd.Method and apparatus for drug delivery
US8469934B2 (en)2010-01-272013-06-25Alcon Research, Ltd.Pulsatile peri-corneal drug delivery device
US20110184358A1 (en)*2010-01-272011-07-28Weiner Alan LPulsatile peri-corneal drug delivery device
US10166142B2 (en)2010-01-292019-01-01Forsight Vision4, Inc.Small molecule delivery with implantable therapeutic device
US8623395B2 (en)2010-01-292014-01-07Forsight Vision4, Inc.Implantable therapeutic device
US8765166B2 (en)2010-05-172014-07-01Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US8939948B2 (en)2010-06-012015-01-27Forsight Vision5, Inc.Ocular insert apparatus and methods
US9937073B2 (en)2010-06-012018-04-10Forsight Vision5, Inc.Ocular insert apparatus and methods
US9033911B2 (en)2010-08-052015-05-19Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US9492315B2 (en)2010-08-052016-11-15Forsight Vision4, Inc.Implantable therapeutic device
US8905963B2 (en)2010-08-052014-12-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US9861521B2 (en)2010-08-052018-01-09Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US10617557B2 (en)2010-08-052020-04-14Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US11679027B2 (en)2010-08-052023-06-20Forsight Vision4, Inc.Combined drug delivery methods and apparatus
US11786396B2 (en)2010-08-052023-10-17Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US10265215B2 (en)2010-08-052019-04-23Forsight Vision4, Inc.Injector apparatus and method for drug delivery
US10874548B2 (en)2010-11-192020-12-29Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US11065151B2 (en)2010-11-192021-07-20Forsight Vision4, Inc.Therapeutic agent formulations for implanted devices
US9668915B2 (en)2010-11-242017-06-06Dose Medical CorporationDrug eluting ocular implant
US12419783B2 (en)2010-11-242025-09-23Glaukos CorporationDrug eluting ocular implant
US10245178B1 (en)2011-06-072019-04-02Glaukos CorporationAnterior chamber drug-eluting ocular implant
WO2012174064A1 (en)2011-06-142012-12-20Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US10398592B2 (en)2011-06-282019-09-03Forsight Vision4, Inc.Diagnostic methods and apparatus
US11813196B2 (en)2011-06-282023-11-14Forsight Vision4, Inc.Diagnostic methods and apparatus
US9102105B2 (en)2011-09-132015-08-11Vista Scientific LlcMethod for forming an ocular drug delivery device
US10835416B2 (en)2011-09-142020-11-17Forsight Vision5, Inc.Ocular insert apparatus and methods
US20200038240A1 (en)*2011-09-142020-02-06Forsight Vision5, Inc.Ocular insert apparatus and methods
US8715712B2 (en)2011-09-142014-05-06Forsight Vision5, Inc.Ocular insert apparatus and methods
US10653554B2 (en)2011-09-162020-05-19Forsight Vision4, Inc.Fluid exchange apparatus and methods
US9883968B2 (en)2011-09-162018-02-06Forsight Vision4, Inc.Fluid exchange apparatus and methods
WO2013058809A1 (en)2011-10-192013-04-25Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
EP2944628A1 (en)2011-11-302015-11-18Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
WO2013081642A1 (en)2011-12-012013-06-06Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US10010448B2 (en)2012-02-032018-07-03Forsight Vision4, Inc.Insertion and removal methods and apparatus for therapeutic devices
US10603209B2 (en)2012-02-032020-03-31Forsight Vision4, Inc.Insertion and removal methods and apparatus for therapeutic devices
US11197780B2 (en)2012-03-262021-12-14Glaukos CorporationSystem and method for delivering multiple ocular implants
US12343288B2 (en)2012-03-262025-07-01Glaukos CorporationSystem and method for delivering multiple ocular implants
US11944573B2 (en)2012-03-262024-04-02Glaukos CorporationSystem and method for delivering multiple ocular implants
US9623215B2 (en)2012-06-012017-04-18Surmodics, Inc.Apparatus and methods for coating medical devices
US10507309B2 (en)2012-06-012019-12-17Surmodics, Inc.Apparatus and methods for coating medical devices
US9308355B2 (en)2012-06-012016-04-12Surmodies, Inc.Apparatus and methods for coating medical devices
US9827401B2 (en)2012-06-012017-11-28Surmodics, Inc.Apparatus and methods for coating medical devices
US10099041B2 (en)2012-06-012018-10-16Surmodics, Inc.Apparatus and methods for coating medical devices
US10456293B2 (en)2012-10-262019-10-29Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US9750636B2 (en)2012-10-262017-09-05Forsight Vision5, Inc.Ophthalmic system for sustained release of drug to eye
US9968603B2 (en)2013-03-142018-05-15Forsight Vision4, Inc.Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US12208034B2 (en)2013-03-152025-01-28Dose Medical CorporationImplants with controlled drug delivery features and methods of using same
US11253394B2 (en)2013-03-152022-02-22Dose Medical CorporationControlled drug delivery ocular implants and methods of using same
US11559430B2 (en)2013-03-152023-01-24Glaukos CorporationGlaucoma stent and methods thereof for glaucoma treatment
US12427057B2 (en)2013-03-152025-09-30Glaukos CorporationControlled drug delivery ocular implants and methods of using same
US11510810B2 (en)2013-03-282022-11-29Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en)2013-03-282024-10-15Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en)2013-03-282019-09-03Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US9526654B2 (en)2013-03-282016-12-27Forsight Vision4, Inc.Ophthalmic implant for delivering therapeutic substances
US11076985B2 (en)2013-11-042021-08-03Tearoptix, Inc.Conjunctival cover and methods therefor
US10449086B2 (en)2013-11-042019-10-22Vance M. ThompsonConjunctival cover and methods therefor
US11672698B2 (en)2013-11-042023-06-13Tearoptix, Inc.Conjunctival cover and methods therefor
US10548767B2 (en)*2013-11-042020-02-04Vance M. ThompsonConjunctival cover and methods therefor
US12076272B2 (en)2013-11-042024-09-03Tearoptix, Inc.Conjunctival cover and methods therefor
US20180092771A1 (en)*2013-11-042018-04-05Vance M. ThompsonConjunctival cover and methods therefor
WO2015071427A1 (en)2013-11-142015-05-21Eyed PharmaEye device
EP3566693A1 (en)2013-11-142019-11-13EyeD PharmaEye device
US11992551B2 (en)2014-05-292024-05-28Glaukos CorporationImplants with controlled drug delivery features and methods of using same
US10959941B2 (en)2014-05-292021-03-30Glaukos CorporationImplants with controlled drug delivery features and methods of using same
US11337853B2 (en)2014-07-152022-05-24Forsight Vision4, Inc.Ocular implant delivery device and method
US12343283B2 (en)2014-07-152025-07-01Forsight Vision4, Inc.Ocular implant delivery device and method
US10258503B2 (en)2014-07-152019-04-16Forsight Vision4, Inc.Ocular implant delivery device and method
US9474756B2 (en)2014-08-082016-10-25Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en)2014-08-082020-09-08Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en)2014-08-082019-07-30Forsight Vision4, Inc.Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en)2014-08-082018-02-20Forsight Vision4, IncStable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016031535A1 (en)*2014-08-282016-03-03株式会社ユニバーサルビューDevice placed under eyelid
JP5671183B1 (en)*2014-08-282015-02-18株式会社ユニバーサルビュー Eyelid interior tools
US11110001B2 (en)2014-11-102021-09-07Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US12251336B2 (en)2014-11-102025-03-18Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US10500091B2 (en)2014-11-102019-12-10Forsight Vision4, Inc.Expandable drug delivery devices and methods of use
US12044904B2 (en)2015-03-112024-07-23Tearoptix, Inc.Tear shaping for refractive correction
US11567348B2 (en)2015-03-112023-01-31Tearoptix, Inc.Tear shaping for refractive correction
US11224602B2 (en)2015-04-132022-01-18Forsight Vision5, Inc.Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US10010502B2 (en)2015-05-192018-07-03Amorphex Therapeutics LlcDevice that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US11654250B2 (en)2015-08-262023-05-23Medtronic Xomed, Inc.Resorbable, drug-eluting submucosal turbinate implant device and method
US10596330B2 (en)2015-08-262020-03-24Medtronic Xomed, Inc.Resorbable, drug-eluting submucosal turbinate implant device and method
US11925578B2 (en)2015-09-022024-03-12Glaukos CorporationDrug delivery implants with bi-directional delivery capacity
US11564833B2 (en)2015-09-252023-01-31Glaukos CorporationPunctal implants with controlled drug delivery features and methods of using same
US11432959B2 (en)2015-11-202022-09-06Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US12201556B2 (en)2015-11-202025-01-21Forsight Vision4, Inc.Porous structures for extended release drug delivery devices
US11617680B2 (en)2016-04-052023-04-04Forsight Vision4, Inc.Implantable ocular drug delivery devices
US12102560B2 (en)2016-04-052024-10-01Forsight Vision4, Inc.Implantable ocular drug delivery devices
US11318043B2 (en)2016-04-202022-05-03Dose Medical CorporationBioresorbable ocular drug delivery device
US11281023B2 (en)2016-10-172022-03-22Tearoptix, Inc.Tear shaping for refractive correction
US12105359B2 (en)2016-10-172024-10-01Tearoptix, Inc.Tear shaping for refractive correction
US11116625B2 (en)2017-09-282021-09-14Glaukos CorporationApparatus and method for controlling placement of intraocular implants
US12226308B2 (en)2017-09-282025-02-18Glaukos CorporationMethod for controlling placement of intraocular implants
US12414798B2 (en)2017-10-062025-09-16Glaukos CorporationSystems and methods for delivering multiple ocular implants
US11376040B2 (en)2017-10-062022-07-05Glaukos CorporationSystems and methods for delivering multiple ocular implants
USD901683S1 (en)2017-10-272020-11-10Glaukos CorporationImplant delivery apparatus
USD938585S1 (en)2017-10-272021-12-14Glaukos CorporationImplant delivery apparatus
US11419759B2 (en)2017-11-212022-08-23Forsight Vision4, Inc.Fluid exchange apparatus for expandable port delivery system and methods of use
US11524032B2 (en)2018-01-052022-12-13University Of Utah Research FoundationTreatment of myopic progression
CN112105320A (en)*2018-01-052020-12-18犹他大学研究基金会Treating myopia progression
WO2019136358A1 (en)*2018-01-052019-07-11Iveena Delivery Systems, Inc.Treatment of myopic progression
JP2019176912A (en)*2018-03-302019-10-17真一 芦田Ophthalmic device, ophthalmic medicament administration device, and ophthalmic mounted article
US12210226B2 (en)2018-04-062025-01-28Tearoptix, Inc.Tear shaping for refractive correction
US11703695B2 (en)2018-04-062023-07-18Tearoptix, Inc.Tear shaping for refractive correction
US11628466B2 (en)2018-11-292023-04-18Surmodics, Inc.Apparatus and methods for coating medical devices
US11819590B2 (en)2019-05-132023-11-21Surmodics, Inc.Apparatus and methods for coating medical devices
US12257184B2 (en)2019-10-242025-03-25Denis LaBombardOcular device and drug delivery system, with case
WO2021081117A2 (en)2019-10-242021-04-29Labombard Denis EOcular device and drug delivery system, with case
WO2023073706A1 (en)2021-10-272023-05-04Avisi Ltd.Ophthalmic device
USD1033637S1 (en)2022-01-242024-07-02Forsight Vision4, Inc.Fluid exchange device
WO2024224394A1 (en)2023-04-272024-10-31Avisi Ltd.Elastomeric matrices comprising polyvinyl alcohol

Similar Documents

PublicationPublication DateTitle
US3416530A (en)Eyeball medication dispensing tablet
US4484922A (en)Occular device
US3995635A (en)Ocular insert
US4201210A (en)Veterinary ocular ring device for sustained drug release
US5147647A (en)Ocular insert for the fornix
US3952735A (en)Eye bandage
US5928662A (en)Ocular drug delivery device
US2920624A (en)Eye drop dispenser
KR101371685B1 (en) Therapeutic contact lenses
US3618604A (en)Ocular insert
US3973838A (en)Contact lenses
US3910618A (en)Contact lens applicator
US4678466A (en)Internal medication delivery method and vehicle
US20090004244A1 (en)Iris design as a drug depot for zonal drug delivery by contact lens
JPH0337066A (en)Instillation tool for eye-water
KR101789278B1 (en)Eyewash applicator
KR101427392B1 (en)Therapeutic contact lens
US3485244A (en)Eye applicator
US4543949A (en)Custom valved cervical cap
US4369219A (en)Custom valved cervical cap with deformable margin
CN203220483U (en)Artificial-crystal drug releasing apparatus capable of opening by laser
US2765789A (en)Eyeshade applicator
US1929228A (en)Contact eyeglass construction
EP0262893A2 (en)Ocular insert
US2347488A (en)Optical lens

[8]ページ先頭

©2009-2025 Movatter.jp